학술논문

EE668 Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Adults and Adolescents Aged 12 Years and Older With Resected Stage IIB/IIC Melanoma in France.
Document Type
Article
Source
Value in Health. 2023 Supplement, Vol. 26 Issue 12, pS182-S182. 1p.
Subject
Language
ISSN
1098-3015